PROSPECTIVE EVALUATION OF PRESCRIBING PRACTICES AND QUALITY OF LIFE OUTCOMES IN MIGRAINE PATIENTS
Main Article Content
Keywords
Migraine, HRQol, HIT-6, prescription pattern, prophylaxis.
Abstract
Background: Migraine is amongst the most common disorders of the central nervous system affecting people throughout the world. Migraine can be managed to some degree by a variety of non-pharmacological and pharmacological treatment includes both acute and preventive therapy. Migraine has also been associated with poor health related quality of life (HRQoL). Such a study is important in India as there is insufficient data on impact of migraine on HRQoL and also the pattern of intake of various drugs associated with migraine.
Material and methods: A total of 200 prescriptions of migraine patients were studied. Patient details were noted on case record form which included demographic information and details of disease. The demographic details and information on drug/drugs prescribed including dose, formulation and dosing frequency for acute as well as prophylactic treatment were noted.
Results: The average number of drugs prescribed per prescription is in line with the WHO core indicators. The use of drugs for migraine prophylaxis had a significant improvement on the quality of life for study participants, based on the HIT-6 scores. At baseline, the mean HIT-6 score was 58.44. At the end of 3 months, the mean score had reduced to 51. A reduction in HIT-6 score indicates a decrease in severity and disability associated with migraine. There was a statistically significant difference between HIT-6 score at baseline and at 3 months. (p value <0.0001). Out of 200 prescriptions, drugs were prescribed by generic names in 70% (140) of the prescriptions. Out of a total of 657 drugs, 209 drugs were prescribed by generic names. The drugs prescribed by generic name were 31.81%.
Conclusion: The prescribing pattern of drugs used for migraine was according to the guidelines. There is a potential for improving drug prescribing by generic name and drugs prescribed from essential drug list. The average number of drugs prescribed per prescription is in line with the WHO core indicators. The use of drugs for migraine prophylaxis had a significant improvement on the quality of life for study participants, based on the HIT-6 scores.
References
2. Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F et.al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211- 59.
3. Ray BK, Paul N, Hazra A, Das S, Ghosal MK, Misra AK et.al. Prevalence, burden, and risk factors of migraine: A community-based study from Eastern India. Neurol Ind. 2017;65:1280-88.
4. Dodson H, Bhula J, Eriksson S, Nguyen K. Pharmacologic treatment of migraine in the emergency department: alternatives to opioids and their effectiveness in relieving migraines and reducing treatment times. Cureus. 2018;10(4):e2439.
5. Stephen D Silberstein, Joshua M Cohen, Paul P Yeung. Fremanezumab for the preventive treatment of migraine. Expert Opin Biol Ther. 2019;19(8):763–71.
6. Mudenda S, Simbaya R, Moonga G, Mwaba F, Zulu M, Tembo R, et al. Antibiotic prescribing patterns in adult patients according to the WHO AWaRe classification: a multi‑facility cross‑sectional study in primary healthcare hospitals in Lusaka, Zambia. Pharmacology & Pharmacy. 2025;16(1):1‑12.
7. Soares AA, Fortes YML, Souza WPO, Silva‑Néto RP. Quality of life in women with migraine: a systematic review. Headache Med. 2024;4(1):44.
8. Bhave K, Tondare S, Pandit P, Patankar R. Drug use pattern and quality of life in patients with migraine at a tertiary care hospital in India: an observational study. Natl J Physiol Pharm Pharmacol. 2022;12(11):1939–43
9. Jyani G, Prinja S, Garg B, Kaur M, Grover S, Sharma A, Goyal A. Health-related quality of life among the Indian population: the EQ-5D population norms for India. J Glob Health. 2023;13:04018.
10. Meena P, Rao R, Sivachandran S, Manoharan P. Assessment of medicine use based on WHO/INRUD core drug-use indicators at primary health centers in Puducherry, India: A prospective study. Br J Clin Pharmacol. 2022;88(7):3234–42.
11. Kernick D, Kondori N, Pain A, et al. Preventive treatment patterns in the adult migraine population: an observational UK study over 7 years. BMC Prim Care. 2024;25:34.
12. Jette N, Patten S, Williams J, Becker W, Wiebe S. Comorbidity of migraine and psychiatric disorders—a national population‐based study. Headache. 2008;48:501-16.
13. Bhatia MS, Gupta R. Migraine: clinical pattern and psychiatric comorbidity. Ind Psychiatry J. 2012;21:18-21.
14. Jena SS, Jena M, Dash M, Mishra S, Behera IC. Migraine: Pattern of Prescription & Adverse Drug Reaction Profile in A Tertiary Care Teaching Hospital. J. Pharm. Sci. & Res. 2015;7:111-6.
15. Andress‐Rothrock D, King W, Rothrock J. An analysis of migraine triggers in a clinic‐based population. Headache. 2010;50:1366-70.
16. Hsu YC, Lin KC. Medical Treatment Guidelines for Acute Migraine Attacks. Acta Neurol Taiwanica. 2017;26:78-96.
17. Salisbury-Afshar E. Topiramate for the prophylaxis of episodic migraine in adults. Am Fam Physician. 2014;90:24.
18. Chandelkar UK, Rataboli PV. A study of drug prescribing pattern using WHO prescribing indicators in the state of Goa, India. Int J Basic Clin Pharmacol. 2017;3:1057-61.
19. Haywood KL, Mars TS, Potter R, Patel S, Matharu M, Underwood M. Assessing the impact of headaches and the outcomes of treatment: A systematic review of patient-reported outcome measures (PROMs). Cephalalgia. 2018;38:1374-86.
20. Rendas-Baum R, Yang M, Varon SF, Bloudek LM, DeGryse RE, Kosinski M. Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine. Health Qual Life Outcomes. 2014;12:117-26.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Angel
Associate professor, Anatomy, Jaipur National University Institute for Medical Sciences and Research Centre
Dr Neethu Mary
Drug Safety Physician, APCER Life Sciences, Delhi
Dr Kailash Chander
Associate professor, Anatomy, Jaipur National University Institute for Medical Sciences and Research Centre
Dr Siddharth Arjun Atwal
Medical officer, Civil Hospital, Malerkotla